← Back to Clinical Trials
Recruiting NCT05704257

NCT05704257 Fetal Repair of Complex Gastroschisis: A Safety and Feasibility Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05704257
Status Recruiting
Phase
Sponsor Baylor College of Medicine
Condition Gastroschisis
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2023-10-20
Primary Completion 2029-12

Trial Parameters

Condition Gastroschisis
Sponsor Baylor College of Medicine
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2023-10-20
Completion 2029-12
Interventions
fetoscopy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to evaluate the safety and feasibility of fetal repair of complex gastroschisis (GS) via a fetoscopic surgical approach by assessing maternal, fetal, neonatal, and infant outcomes in a cohort of 10 patients. The hypothesis is that in utero repair of GS will reduce postnatal mortality and morbidity in complex GS infants with minimal maternal and fetal risk.

Eligibility Criteria

Inclusion Criteria: 1. Pregnant women - maternal age 18 years or older and capable of consenting for her own participation in this study 2. Singleton pregnancy 3. Sonographic evidence of gastroschisis (exteriorization of bowel content outside the fetal abdominal cavity into the amniotic cavity) 4. Intraabdominal bowel dilation ≥ 8 mm at 20-24 weeks GA reviewed by prenatal ultrasound 5. Absence of significant associated anomalies\* diagnosed on prenatal ultrasound or MRI 6. Gestational age at the time of the procedure will be between 20 0/7 weeks and 27 6/7 weeks 7. Absence of chromosomal and clinically significant abnormalities, i.e., normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). If there is a balanced translocation with normal CMA with no other anomalies the candidate can be included. Results by fluorescence in situ hybridization (FISH) will be accepted, if the candidate's gestation age is ≥ 22 0/7 w

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology